Xencor (XNCR) Stock Forecast & Price Target

Xencor is viewed favorably because XmAb819 is showing clinically meaningful early activity in heavily pretreated ccRCC, with ORR of 27% in 60 target-dose patients, DCR of 68%, and 26% ORR even after prior HIF2α therapy, suggesting a differentiated opportunity as treatment sequencing evolves. The data also appear to support a manageable safety profile, with predominantly low-grade CRS, low discontinuation rates, and 15 of 16 responders still on treatment at cutoff, which strengthens confidence in RP3D selection and progression toward a pivotal study planned for 2027. Beyond XmAb819, the company’s platform remains attractive because it generates revenue from collaboration and licensing agreements, while recent 2Q26 EPS of $(0.29) benefited from $27.6 million in U.S. Ultomiris royalty revenue and a $10 million Zenas milestone, reinforcing financial resilience as the pipeline advances.

Xencor is a high-risk clinical-stage company whose valuation depends heavily on unproven XmAb programs, with material downside if any candidate fails in the clinic, misses regulatory approval, or does not achieve expected sales. Its oncology and autoimmune trials are described as inherently unpredictable, and even positive data may not be enough if competitors raise efficacy or safety expectations. Financially, the company will need additional capital before commercialization of its wholly owned portfolio, while lower-than-expected royalty payments from partnered programs could further pressure performance and investor confidence.